Global WholeHealth Partners Corp (GWHP) is confident in the new partnerships to produce the best COVID antigen test on the market.
San Clemente, Calif., September 29, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – The COVID antigen test is not going away and has become the new test and vaccine for years to come.
Global WholeHealth Partners Corp. (OTC: GWHP) offers one of the largest ranges of COVID 19 tests. Global WholeHealth Partners Corp (OTC: GWHP) states that the IgG / IgM antibody tests they offer are capable of detecting all currently identified SARS-CoV-2 viruses. The strains identified in the United Kingdom (B.1.1.7), South Africa (B.1.351) and Brazil (P.1) contains multiple mutations, most of which are reflected in the S gene, which encodes the spike protein. Global understands the need to be ahead of the virus to beat the virus. Now, with the vaccine, Global has one of the largest product lines to fight this virus.
Global understands that this is a war on COVID 19 and we are expanding our product line to be able to fight it. With a facility now in the Philippines, Global will be able to better combat the COVID war by fighting in some of the regions of the world that have not been served.
Global WholeHealth Partners recognizes that there is a critical need for faster testing and faster results when it comes to fighting COVID. Global WholeHealth Partners knows that the sooner test results can be reviewed by a frontline health worker, the sooner we can stop the spread of this disease.
With results in minutes instead of hours or days with other diagnostic kits, the more lives you can save with the only FDA-cleared COVID-19 POC point-of-care serology test. With the new finger test, healthcare professionals can prick a patient’s finger and get results in minutes without having to wait for venous blood. Global WholeHealth Partners will be able to distribute these tests to more urgent care, hospitals and – to help curb the spread of CoViD19 SARS2.
As a third wave of the coronavirus threatens much of the United States, public health experts across the country say there is still not enough testing available to keep the virus under control. With the continuous mutation of the virus, Global follows the demand and follows the continuous changes of the virus in the R & D tests.
Global WholeHealth Partners Corp. provides advanced technology using in vitro diagnostic (IVD) real-time PCR machines for the detection of IgM / IgG antibodies to SARS-CoV-2 in human serum, plasma or whole blood. He has led the fight against terminal vector-borne diseases such as Ebola, ZIKA, dengue, malaria, influenza and tuberculosis, Corona viruses, and among other vector-borne diseases FDA Exportability Certificate (2260-11 -2019). The company was founded on March 7, 2013 and is headquartered in San Clemente, California.
GWHP develops, manufactures and markets in vitro diagnostic (IVD) tests for OTC or consumer use, as well as professional rapid point-of-care (POC) diagnostic test kits for hospitals, practices of physicians and medical clinics in the United States and abroad. Notably, Global offers 56 FDA approved products and many are approved for over the counter use, and 25 FDA approved POC products.
The Company makes no express or implied representation that its product has the ability to eliminate, cure, or contain Covid-19 (or SARS-2 Coronavirus) at this time.
Name: Charles Strongo,
CEO, Global WholeHealth Partners Corp.
Email: [email protected] Sales Phone: 877-568-4947
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intention”, “may”, “will”, “plan”, “expect”, “anticipate”, “projects”, “predict”, “estimate”, “aim”. , “Esteem”, “hopes”, “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company, and cannot be predicted or quantified and, by therefore, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, without limitation, the risks and uncertainties associated with (i) market acceptance of our products, (ii) negative clinical trial results or long production delays in markets. keys, (iii) an inability to obtain regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger multinational companies, (v) p liability claims due to the products, (vi) product malfunctions, (vii) our limited manufacturing capabilities and our reliance on subcontractors for support, (viii) insufficient or inadequate reimbursement by government and other payers third parties for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the system in the United States and overseas jurisdictions, (xi) our dependence on single-source suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business needs in the future and that such raising of capital may be costly, dilutive or difficult to obtain and (xiii) the fact that we operate in several foreign jurisdictions, exposing us to exchange rate fluctuations, logistical challenges and communication, burdens and costs of complying with foreign laws and policies, and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements are set out in the documents filed by the Company with the Securities and Exchange Commission (SEC), including the Company’s annual report on the form 10-K and its quarterly report Reports on Form 10-Q. Investors and security holders are encouraged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.